Guangji pharmaceutical will spend no more than 30 million yuan to buy back shares of the company for equity incentive

[China Pharmaceutical Network Enterprise News 】On December 25, Guangji pharmaceutical recently announced that the company decided to use its own funds to buy back the company's shares in the form of centralized competitive trading, with a maximum amount of 30 million yuan, a maximum price of 13 yuan per share, and a buyback period of no more than six months The shares bought back are used for subsequent equity incentive plans, employee stock ownership plans and other purposes permitted by national policies and regulations Way It is understood that the company issued RMB common shares (A shares) According to the high repurchase price of 13 yuan / share and the lower limit of 20 million yuan, it is estimated that the number of shares to be repurchased is about 1.5385 million, accounting for 0.61% of the company's current total share capital; according to the high repurchase price of 13 yuan / share and the upper limit of 30 million yuan, it is estimated that the number of shares to be repurchased is about 2.377 million, accounting for 0.92% of the company's current total share capital The number of shares eventually repurchased by the company shall not exceed 10% of the total share capital The specific number of shares repurchased shall be subject to the actual number of shares repurchased at the expiration of the repurchase period As of September 30, 2018, the company's unaudited financial data are as follows: the company's total assets are 1.613 billion yuan, and the net assets attributable to shareholders of the listed company are 864 million yuan Assuming that the upper limit of the buyback fund is 30 million yuan, according to the unaudited financial data on September 30, 2018, the buyback fund accounts for about 1.86% of the company's total assets and 3.47% of the net assets attributable to shareholders of the listed company According to the data of dig Beiwang, the main products of Guangji pharmaceutical industry are divided into raw material series products and preparation series products The raw material series products are pharmaceutical grade, food grade, 98% feed grade, 80% feed grade riboflavin and riboflavin sodium phosphate; the preparation series products are oral solid preparation and infusion.